Skip to main
CNTA
CNTA logo

CNTA Stock Forecast & Price Target

CNTA Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Centessa Pharmaceuticals PLC is poised for substantial growth in its ORX750 product, as market share projections for orexin agonists in Narcolepsy Type 2 (NT2) and Idiopathic Hypersomnia (IH) have been increased to 60%, reflecting the widening therapeutic potential of its pipeline. Furthermore, the company's clinical studies suggest that management may achieve greater efficacy in treating Narcolepsy Type 1 (NT1) compared to competitors, enhancing its competitive positioning and revenue generation potential. Additionally, the evolution of other products in its pipeline, such as ORX142 and ORX489, indicates a strategic expansion into neurodegenerative and neuropsychiatric disorders, broadening Centessa’s market reach and reinforcing a positive long-term outlook.

Bears say

Centessa Pharmaceuticals exhibits fundamental concerns due to the declining efficacy of its key asset, Oveporexton, which showed a significant drop in placebo-adjusted mean wakefulness time (MWT) from 23 minutes in phase 2b trials to below 20 minutes in phase 3 trials. Additionally, uncertainties surrounding the long-term efficacy of orexin agonists for various sleep disorders, coupled with the challenges posed by substantial placebo effects and baseline variability in clinical trials, further complicate their product's therapeutic potential. These factors raise a red flag regarding the robustness of Centessa's clinical pipeline and its ability to achieve sustainable commercial viability.

CNTA has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Centessa Pharmaceuticals PLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Centessa Pharmaceuticals PLC (CNTA) Forecast

Analysts have given CNTA a Buy based on their latest research and market trends.

According to 8 analysts, CNTA has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Centessa Pharmaceuticals PLC (CNTA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.